Filing Flows › Madrigal Pharmaceuticals (MDGL) › Who owns the stock
Who owns Madrigal Pharmaceuticals (MDGL) stock
408 funds reported Madrigal Pharmaceuticals (MDGL) shares in their latest 13F filings, worth $14.5B in all. The largest holder is Baker Bros. Advisors LP ($1.2B). Last quarter 196 funds added to their stakes and 162 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 2,143,131 | $1.2B | increase | 2026-06-30 |
| RTW Investments, LP | 1,993,687 | $1.1B | unchanged | 2026-06-30 |
| Vanguard Group | 1,808,894 | $1.1B | decrease | 2025-12-31 |
| Janus Henderson Group | 2,018,647 | $1.1B | increase | 2026-03-31 |
| Jupiter Topco LLC | 1,936,099 | $1.0B | base | 2026-06-30 |
| Avoro Capital Advisors LLC | 1,833,333 | $984M | increase | 2026-06-30 |
| Paulson | 1,340,020 | $720M | decrease | 2026-06-30 |
| BlackRock | 1,200,770 | $645M | decrease | 2026-06-30 |
| Vanguard Capital Management LLC | 835,668 | $449M | increase | 2026-06-30 |
| Wellington Management Group LLP | 825,714 | $443M | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 781,731 | $420M | decrease | 2026-06-30 |
| State Street | 527,057 | $283M | decrease | 2026-06-30 |
| Citadel Advisors LLC | 507,233 | $272M | increase | 2026-06-30 |
| UBS Group AG | 401,708 | $216M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 374,880 | $201M | decrease | 2026-06-30 |
Madrigal Pharmaceuticals' latest quarter
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most MDGL stock?
By the latest 13F filings: Baker Bros. Advisors LP ($1.2B); RTW Investments, LP ($1.1B); Vanguard Group ($1.1B); Janus Henderson Group ($1.1B); Jupiter Topco LLC ($1.0B).
What is the short interest in MDGL?
2,194,545 shares were sold short at the 2026-10-15 settlement, -8.42% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.